Tobira Therapeutics Inc. (TBRA): Pentwater Capital Management Reports New Position

Item 1(a).

Name of Issuer:

Tobira Therapeutics, Inc

Item 1(b).

Address of Issuer’s Principal Executive Offices:

701 Gateway Boulevard, Suite 300

South San Francisco, CA 94080

Item 2(a).

Name of Person Filing:

Pentwater Capital Management, LP

Item 2(b).

Address of Principal Business Office, or if None, Residence:

614 Davis Street

Evanston, IL 60201

Item 2(c).

Citizenship:

Delaware, USA

Item 2(d).

Title of Class of Securities:

Common Stock, $0.001 par value

Item 2(e).

CUSIP Number: 88883P101

Item 3.

If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

(a)	☐	Broker or dealer registered under Section 15 of the Exchange Act.

(b)	☐	Bank as defined in Section 3(a)(6) of the Exchange Act.

(c)	☐	Insurance company as defined in Section 3(a)(19) of the Exchange Act.

(d)	☐	Investment company registered under Section 8 of the Investment Company Act.

(e)	☑	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

(i)	☐	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

(j)	☐	Group, in accordance with

Page 4 of 6 – SEC Filing